Organogenesis Holdings Inc.

Equities

ORGO

US68621F1021

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-03 EDT			5-day change	1st Jan Change
2.6 ^USD	-5.45%		-1.14%	-36.43%

05-13	Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating	MT
05-10	Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup	DJ

Organogenesis Holdings Inc. Announces the Appointment of Jon Giacomin to its Board of Directors

May 10, 2021 at 07:30 am

Organogenesis Holdings Inc. announced the appointment of Jon Giacomin to the Company’s Board of Directors, effective May 7, 2021. Mr. Giacomin currently serves as the Chief Executive Officer of U.S. Anesthesia Partners Inc.

Latest news about Organogenesis Holdings Inc.

Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating	05-13	MT
Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup	05-10	DJ
Earnings Flash (ORGO) ORGANOGENESIS HOLDINGS Posts Q1 Revenue $110M, vs. Street Est of $101.1M	05-09	MT
Transcript : Organogenesis Holdings Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Organogenesis Holdings Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024	05-09	CI
Organogenesis Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis	05-02	CI
Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024	02-29
Organogenesis Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Earnings Flash (ORGO) ORGANOGENESIS HOLDINGS Posts Q4 Revenue $99.7M, vs. Street Est of $109.1M	02-29	MT
Organogenesis Holdings Inc. Provides Earnings Guidance for the First Quarter and for the Year Ending December 31, 2024	02-29	CI
Organogenesis Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Organogenesis Holdings Insider Sold Shares Worth $940,860, According to a Recent SEC Filing	01-11	MT
BTIG Raises Price Target on Organogenesis Holdings to $6 From $4, Keeps Buy Rating	12-27	MT
Morgan Stanley Adjusts Price Target on Organogenesis to $3.50 From $3, Maintains Equalweight Rating	11-14	MT
Transcript : Organogenesis Holdings Inc., Q3 2023 Earnings Call, Nov 09, 2023	11-09
Earnings Flash (ORGO) ORGANOGENESIS HOLDINGS Posts Q3 Revenue $108.5M, vs. Street Est of $111.4M	11-09	MT
Organogenesis Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2023	11-09	CI
Transcript : Organogenesis Holdings Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 08:00 AM	23-09-11
Stocks wilt after early promise with US closed	23-09-04	AN
Hopes of rate peak, China turnaround lift stocks	23-09-04	AN
AIM WINNERS & LOSERS: Physiomics brings in COO; Ergomed receives bid	23-09-04	AN
Advanced Medical issues profit warning following royalty issues	23-09-04	AN
Advanced Medical Solutions Group Updates FY23 Guidance	23-09-04	MT

Chart Organogenesis Holdings Inc.

Duration

Period

More charts

Company Profile

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting.

Sector

Biotechnology & Medical Research

Calendar

2024-06-20 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Organogenesis Holdings Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.6 USD

Average target price

4.667 USD

Spread / Average Target

+79.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ORGANOGENESIS HOLDINGS INC.	-36.43%	365M
MODERNA, INC.	+48.64%	54.63B
IQVIA HOLDINGS INC.	-6.44%	39.92B
LONZA GROUP AG	+37.07%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.28%	26.86B
CELLTRION, INC.	-11.17%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-21.40%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.64%	12.21B
BIO-TECHNE CORPORATION	+0.96%	12.16B
MEDPACE HOLDINGS, INC.	+27.04%	11.94B

Other Biotechnology & Medical Research